Loading...
•
Mar 31, 2020
TransMedics Q1 2020 Earnings Report
Reported financial results for the quarter ended March 31, 2020.
Key Takeaways
TransMedics reported a strong start to 2020 with a 61% increase in net revenue, driven by OCS adoption in the US and internationally. The company is taking measures to preserve cash and mitigate risks during the COVID-19 pandemic.
Net revenue for Q1 2020 was $7.5 million, a 61% increase compared to $4.7 million in Q1 2019.
Gross margin for Q1 2020 was 65% compared to 55% in Q1 2019.
Net loss for Q1 2020 was $8.9 million compared to $6.9 million in Q1 2019.
Cash, cash equivalents and marketable securities were $72.6 million as of March 31, 2020.
Forward Guidance
TransMedics withdrew its annual guidance for 2020 due to the unpredictability of the duration and the magnitude of the impact that the COVID-19 pandemic will have on its financial and operating results.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...